Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
Malignant Mesothelioma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The time to confirm a diagnosis of malignant mesothelioma and the rate of disease progression both vary greatly. This makes it difficult to assess prognosis for these patients. In large retrospective series of patients with pleural mesothelioma, the following important prognostic factors were identified:[1,2][Level of evidence C1]
Sources: 1 · 2 · Level of evidence C1
Stage.
Age.
Performance status (PS).
Histology.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Two prognostic scoring systems have been developed for advanced unresectable mesothelioma and are used to stratify patients enrolling in clinical trials: the Cancer and Leukemia Group B (CALGB) index and the European Organisation for the Research and Treatment of Cancer (EORTC) index.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The CALGB index was developed retrospectively using the clinical characteristics of 337 patients treated in clinical trials of chemotherapy for advanced mesothelioma during a 10-year period.[3][Level of evidence C1] These characteristics were used collectively to define six prognostic groups with median survivals ranging from 13.9 months (Eastern Cooperative Oncology Group [ECOG] PS = 0, age <49 years; or PS = 0, age ≥49 years and hemoglobin ≥14.6 g/dL) to 1.4 months (PS = 1 or 2 and white blood cell [WBC] count ≥15.6 × 109/L).
Sources: 3 · Level of evidence C1
The prognostic value of the CALGB index was evaluated retrospectively in a phase II clinical trial of 105 patients.[4][Level of evidence C1] Median survival in this study for patients in the best CALGB prognostic group was 29.9 months, compared with 1.8 months for patients in the worst prognostic group. However, the intermediate groups 2 to 4 overlapped in their survival times.
Sources: 4 · Level of evidence C1
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
The EORTC index was also developed retrospectively using the characteristics of 181 patients from five phase II clinical trials of chemotherapy during a 9-year period.[5][Level of evidence C1] In a multivariate analysis, the following characteristics were associated with poorer survival:
Sources: 5 · Level of evidence C1
WBC count >8.3 × 109/L.
ECOG PS ≥1.
Unconfirmed histology on central review.
Nonepithelioid histology.
Male sex.
Patients were allocated a numerical prognostic score based on each of these variables (+0.55 if WBC >8.3 × 109/L, +0.60 if ECOG PS ≥1, +0.52 if unconfirmed histology, and +0.60 if male sex). Subsequently, patients were classified into two prognostic groups that included low-risk patients with a prognostic score of 1.27 or lower (0–2 risk factors) and high-risk patients with a prognostic score higher than 1.27 (3–5 risk factors). High-risk patients had a relative risk of death of 2.9 compared with low-risk patients (P < .001). The 1-year survival rate was 40% for the low-risk group compared with 12% for the high-risk group.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Patients with limited disease may consider multimodality therapy incorporating radical surgery (extrapulmonary pneumonectomy or radical pleurectomy with decortication) given with or without chemotherapy and/or radiation therapy. Multimodality therapy has been associated with a relatively long survival in observational series.[6][Level of evidence C1] For patients treated with aggressive surgical approaches, the following factors are associated with improved long-term survival:[7,8][Level of evidence C2]
Sources: 6 · Level of evidence C1 · 7 · 8 · Level of evidence C2
Epithelioid histology.
Negative lymph nodes.
Negative surgical margins.
For patients treated with aggressive surgical approaches, nodal status is an important prognostic factor.[7] Median survival has been reported as 16 months for patients with malignant pleural disease and 5 months for patients with extensive disease. In some instances, the tumor grows through the diaphragm, making the site of origin difficult to assess. Cautious interpretation of treatment results with this disease is imperative because of the selection differences among series. Effusions, both pleural and peritoneal, represent major symptomatic problems for at least 66% of patients. For more information, see Cardiopulmonary Syndromes.
Sources: 7 · Cardiopulmonary Syndromes
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Standard treatment for all but localized mesothelioma is generally not curative. Some patients will experience long-term survival with aggressive treatment approaches, but it remains unclear if overall survival (OS) is significantly altered by different treatment modalities or combinations of modalities.
Extrapleural pneumonectomy may improve the recurrence-free survival of selected patients with early-stage disease, but the impact on OS is unknown.[1] Pleurectomy and decortication can provide palliative relief from symptomatic effusions, discomfort caused by tumor burden, and pain caused by invasive tumor. For more information, see Cancer Pain. Trimodality therapy refers to a combination of chemotherapy, definitive surgery, and radiation therapy. Because of the rarity of mesothelioma and the complexities of patient selection, surgical technique, and optimal sequencing of therapy, delivery of such therapy in centers with established experience and expertise in the management of mesothelioma has shown better results. Operative mortality from pleurectomy with decortication is less than 2%,[2] while mortality from extrapleural pneumonectomy ranges from 6% to 30%.[1,3]
Sources: 1 · Cancer Pain · 2 · 1 · 3
Several single-arm phase II studies have demonstrated prolonged survival times (compared with historical controls) for selected patients who received adjuvant radiation therapy after definitive surgery.[2,4,5] Most patients with pleural mesothelioma who receive radiation therapy experience pain relief, but symptom control is short-lived.[6,7] Other single-arm phase II studies investigated neoadjuvant chemotherapy (mainly with platinum and pemetrexed or gemcitabine) followed by definitive surgery and adjuvant radiation therapy.[8-10] These studies have also shown prolonged survival compared with historical controls; however, this advantage has yet to be confirmed in a randomized study.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for localized malignant mesothelioma (stage I) include:[1]
Sources: 1
Surgery. Solitary mesotheliomas are treated with surgical resection en bloc including contiguous structures to ensure wide disease-free margins. Sessile polypoid lesions are treated with surgical resection to ensure maximal potential for cure.[2] Intracavitary mesotheliomas are treated with extrapleural pneumonectomy.
Sources: 2
Palliative surgery. Pleurectomy and decortication with or without postoperative radiation therapy may be used for intracavitary mesothelioma.
Palliative radiation therapy (for intracavitary mesothelioma).
Clinical trials.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for advanced malignant mesothelioma (stages II, III, and IV) include:
First-line systemic therapy.
Sources: First-line systemic therapy
Cisplatin plus pemetrexed, with or without bevacizumab.[2-4]
Sources: Cisplatin plus pemetrexed, with or without bevacizumab · 2 · 4
Durvalumab with platinum plus pemetrexed.[5]
Sources: Durvalumab with platinum plus pemetrexed · 5
Platinum plus pemetrexed, followed by best supportive care, with or without maintenance gemcitabine.[6]
Sources: Platinum plus pemetrexed, followed by best supportive care, with or without maintenance gemcitabine · 6
Symptomatic treatment to include drainage of effusions, chest tube pleurodesis, or thoracoscopic pleurodesis.[11] For more information, see Cardiopulmonary Syndromes.
Sources: 11 · Cardiopulmonary Syndromes
Intracavitary therapy. Intrapleural or intraperitoneal administration of chemotherapeutic agents (e.g., cisplatin, mitomycin, and cytarabine) has been reported to produce transient reduction in the size of tumor masses and temporary control of effusions in small clinical studies.[16-18] Additional studies are needed to define the role of intracavitary therapy.
Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
First-line systemic therapy
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (nivolumab and ipilimumab):
An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]
Sources: CheckMate743 · 1
An open-label, randomized, phase III study (CheckMate743 [NCT02899299]) included 605 patients with advanced treatment-naive pleural mesothelioma. Patients were randomly assigned to receive either nivolumab and ipilimumab (n = 303) or chemotherapy (n = 302).[1]
At the prespecified interim analysis, patients who received nivolumab plus ipilimumab had significantly extended overall survival (OS) compared with patients who received chemotherapy (median OS, 18.1 months [95% confidence interval (CI), 16.8–21.4] vs. 14.1 months [12.4–16.2]; hazard ratio [HR], 0.74; 96.6% CI, 0.60–0.91; P = .002).[1][Level of evidence A1]
Sources: 1 · Level of evidence A1
The median progression-free survival (PFS) and objective response rates were not significantly different.
Grade 3 to 4 treatment-related adverse events occurred in 91 of 300 patients (30%) who received nivolumab plus ipilimumab and 91 of 284 patients (32%) who received chemotherapy.
Three (1%) treatment-related deaths occurred among patients who received nivolumab plus ipilimumab (pneumonitis, encephalitis, and heart failure) and one (<1%) among patients who received chemotherapy (myelosuppression).
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (cisplatin plus pemetrexed, with or without bevacizumab):
A randomized phase III trial demonstrated the safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery.[4][Level of evidence A1] This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously [IV] every 21 days). With 456 patients enrolled in the trial, 226 patients received pemetrexed plus cisplatin, 222 patients received cisplatin alone, and 8 patients did not receive therapy.After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects.Dexamethasone (4 mg) or an equivalent corticosteroid was given orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose.
Sources: 4 · Level of evidence A1
A randomized phase III trial demonstrated the safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery.[4][Level of evidence A1] This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously [IV] every 21 days). With 456 patients enrolled in the trial, 226 patients received pemetrexed plus cisplatin, 222 patients received cisplatin alone, and 8 patients did not receive therapy.After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects.Dexamethasone (4 mg) or an equivalent corticosteroid was given orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose.
Folic acid (350–1,000 µg PO) was given daily, beginning 1 to 3 weeks before the first chemotherapy dose and continuing daily until 1 to 3 weeks after treatment ended.
A vitamin B12 injection (1,000 µg intramuscularly) was given 1 to 3 weeks before the first chemotherapy dose and was repeated approximately every 9 weeks until treatment ended.
In an analysis of all patients who were randomly assigned and treated, the combination of pemetrexed and cisplatin was associated with a statistically significant improvement in survival compared with cisplatin alone.
A randomized phase III trial demonstrated the safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery.[4][Level of evidence A1] This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously [IV] every 21 days). With 456 patients enrolled in the trial, 226 patients received pemetrexed plus cisplatin, 222 patients received cisplatin alone, and 8 patients did not receive therapy.After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects.Dexamethasone (4 mg) or an equivalent corticosteroid was given orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose. › In an analysis of all patients who were randomly assigned and treated, the combination of pemetrexed and cisplatin was associated with a statistically significant improvement in survival compared with cisplatin alone.
The median survival was 12.1 months in the pemetrexed-plus-cisplatin arm and 9.3 months in the cisplatin-alone arm (P = .020).
The HR for death of patients in the pemetrexed-plus-cisplatin arm, compared with those in the control arm, was 0.77.
Median time-to-progression was significantly longer in the pemetrexed-plus-cisplatin arm (5.7 months vs. 3.9 months; P = .001).
A randomized phase III trial demonstrated the safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery.[4][Level of evidence A1] This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously [IV] every 21 days). With 456 patients enrolled in the trial, 226 patients received pemetrexed plus cisplatin, 222 patients received cisplatin alone, and 8 patients did not receive therapy.After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects.Dexamethasone (4 mg) or an equivalent corticosteroid was given orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose.
This superiority in the combination arm was also demonstrated in the vitamin-supplemented subgroup.
A randomized phase III trial demonstrated the safety and efficacy of pemetrexed, an antifolate, and cisplatin in chemotherapy-naive patients with malignant mesothelioma who were not eligible for curative surgery.[4][Level of evidence A1] This trial compared pemetrexed (500 mg/m2) and cisplatin (75 mg/m2 on day 1) with cisplatin alone (75 mg/m2 on day 1 intravenously [IV] every 21 days). With 456 patients enrolled in the trial, 226 patients received pemetrexed plus cisplatin, 222 patients received cisplatin alone, and 8 patients did not receive therapy.After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxic effects.Dexamethasone (4 mg) or an equivalent corticosteroid was given orally twice daily for skin rash prophylaxis to all patients 1 day before, on the day of, and 1 day after each pemetrexed dose. › This superiority in the combination arm was also demonstrated in the vitamin-supplemented subgroup.
The median survival was 13.3 months in the combination arm and 10.0 months in the cisplatin-alone arm (P = .051).
The principal adverse effects of the pemetrexed-plus-cisplatin regimen were myelosuppression, fatigue, nausea, vomiting, and dyspnea.
Most grade 3 to 4 adverse effects were significantly reduced by vitamin supplementation, without any decrease in efficacy.
A randomized controlled, open-label, phase III trial (IFCT-GFPC-0701 [NCT00651456]) evaluated the addition of bevacizumab to chemotherapy and showed an improved OS with the three-drug regimen.[3] The trial included 448 patients with unresectable malignant pleural mesothelioma who had not received previous chemotherapy. Patients had an Eastern Cooperative Oncology Group performance status of 0 to 2 and had no contraindications to bevacizumab, including the use of antiplatelet agents, anticoagulants, and nonsteroidal anti-inflammatory agents. Patients were randomly assigned to receive IV pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) (PC) with or without bevacizumab (15 mg/kg) (PCB) in 21-day cycles for up to six cycles, until disease progression or toxic effects were seen.Combination immune checkpoint inhibitor therapy may be considered as an alternative to combination chemotherapy.
Sources: IFCT-GFPC-0701 · 3
A randomized controlled, open-label, phase III trial (IFCT-GFPC-0701 [NCT00651456]) evaluated the addition of bevacizumab to chemotherapy and showed an improved OS with the three-drug regimen.[3] The trial included 448 patients with unresectable malignant pleural mesothelioma who had not received previous chemotherapy. Patients had an Eastern Cooperative Oncology Group performance status of 0 to 2 and had no contraindications to bevacizumab, including the use of antiplatelet agents, anticoagulants, and nonsteroidal anti-inflammatory agents. Patients were randomly assigned to receive IV pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) (PC) with or without bevacizumab (15 mg/kg) (PCB) in 21-day cycles for up to six cycles, until disease progression or toxic effects were seen.Combination immune checkpoint inhibitor therapy may be considered as an alternative to combination chemotherapy.
The primary outcome was OS in the intention-to-treat population.
OS was significantly longer with PCB (median, 18.8 months; 95% CI, 15.9–22.6) than with PC (median, 16.1 months; 95% CI, 14.0–17.9; HR, 0.77; 0.62–0.95; P = .0167).
Overall, 158 of 222 patients (71%) who received PCB and 139 of 224 patients (62%) who received PC had grade 3 to 4 adverse events.
A randomized controlled, open-label, phase III trial (IFCT-GFPC-0701 [NCT00651456]) evaluated the addition of bevacizumab to chemotherapy and showed an improved OS with the three-drug regimen.[3] The trial included 448 patients with unresectable malignant pleural mesothelioma who had not received previous chemotherapy. Patients had an Eastern Cooperative Oncology Group performance status of 0 to 2 and had no contraindications to bevacizumab, including the use of antiplatelet agents, anticoagulants, and nonsteroidal anti-inflammatory agents. Patients were randomly assigned to receive IV pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) (PC) with or without bevacizumab (15 mg/kg) (PCB) in 21-day cycles for up to six cycles, until disease progression or toxic effects were seen.Combination immune checkpoint inhibitor therapy may be considered as an alternative to combination chemotherapy. › Overall, 158 of 222 patients (71%) who received PCB and 139 of 224 patients (62%) who received PC had grade 3 to 4 adverse events.
Patients who received PCB had more grade 3 or higher hypertension (51 of 222 [23%] vs. 0) and thrombotic events (13 of 222 [6%] vs. 2 of 224 [1%]) than patients who received PC.[3][Level of evidence A1]
Sources: 3 · Level of evidence A1
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (durvalumab with platinum plus pemetrexed):
A phase II, single-arm, multicenter trial (PrE0505 [NCT02899195]) included 55 patients with unresectable, treatment-naive, pleural mesothelioma. Patients received up to six cycles of durvalumab (an anti–programmed death-ligand 1 [PD-L1] antibody) with a platinum plus pemetrexed. The primary end point was OS compared with historical controls (cisplatin and pemetrexed).[5]
A phase II, single-arm, multicenter trial (PrE0505 [NCT02899195]) included 55 patients with unresectable, treatment-naive, pleural mesothelioma. Patients received up to six cycles of durvalumab (an anti–programmed death-ligand 1 [PD-L1] antibody) with a platinum plus pemetrexed. The primary end point was OS compared with historical controls (cisplatin and pemetrexed).[5]
After a median follow-up of 24.2 months, the median OS was 20.4 months (95% CI, 13.0–28.5) for patients in the durvalumab arm compared with the historical control of 12.1 months (HR, 0.034; one-sided P = .0014).[5][Level of evidence C1]
Sources: 5 · Level of evidence C1
The median PFS was 6.7 months (95% CI, 6.1–8.4), and the objective response rate was 56.4% (95% CI, 42.3%–69.7%).
In a non-predefined subgroup analysis, patients with epithelioid malignant pleural mesothelioma had a higher objective response rate (65.9% vs. 28.6%; P = .03), and longer median OS (24.3 months vs. 9.2 months; HR, 0.27; 95% CI, 0.13–0.57; P < .001) than patients with nonepithelioid malignant pleural mesothelioma.
Responding tumors with epithelioid histology were characterized by a higher degree of genomic instability. Favorable clinical outcomes were also observed in patients with a higher immunogenic mutational burden and a more diverse T-cell repertoire, and in individuals with germline alterations in cancer-predisposing genes.
Grade 3 or higher treatment-related adverse events occurred in 65.5% of patients and included anemia (20%), hyponatremia (9%), fatigue (7%), leukopenia (5%), thrombocytopenia (5%), and hypertension (5%). There were no treatment-related deaths.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (platinum plus pemetrexed, followed by best supportive care, with or without maintenance gemcitabine):
A randomized, open-label, phase II clinical trial (NVALT19 [Netherlands Trial Registry ID NTR4132/NL3847]) included 130 patients with unresectable malignant mesothelioma and no evidence of disease progression after at least four cycles of first-line chemotherapy with platinum plus pemetrexed. Patients were randomly assigned (1:1) to receive either maintenance IV gemcitabine (1,250 mg/m2 on days 1 and 8 of 21-day cycles) plus supportive care (n = 65), or to receive best supportive care alone (n = 65). Patients received treatment until disease progression, unacceptable toxicity, serious intercurrent illness, need for other anticancer therapy (except for palliative radiotherapy), or patient request for discontinuation. The primary end point was PFS in the intention-to-treat population.[6]The study demonstrated delayed disease progression in patients receiving maintenance gemcitabine, but the effect on OS is unclear.
Sources: 6
A randomized, open-label, phase II clinical trial (NVALT19 [Netherlands Trial Registry ID NTR4132/NL3847]) included 130 patients with unresectable malignant mesothelioma and no evidence of disease progression after at least four cycles of first-line chemotherapy with platinum plus pemetrexed. Patients were randomly assigned (1:1) to receive either maintenance IV gemcitabine (1,250 mg/m2 on days 1 and 8 of 21-day cycles) plus supportive care (n = 65), or to receive best supportive care alone (n = 65). Patients received treatment until disease progression, unacceptable toxicity, serious intercurrent illness, need for other anticancer therapy (except for palliative radiotherapy), or patient request for discontinuation. The primary end point was PFS in the intention-to-treat population.[6]The study demonstrated delayed disease progression in patients receiving maintenance gemcitabine, but the effect on OS is unclear.
After a median follow-up of 36.5 months, the median PFS was 6.2 months in the gemcitabine group (95% CI, 4.6–8.7) and 3.2 months (95% CI, 2.8–4.1) in the supportive-care group (HR, 0.48; 95% CI, 0.33–0.71; P = .0002). The PFS benefit was confirmed by masked independent central review (HR, 0.49; 95% CI, 0.33–0.72; P = .0002).[6][Level of evidence B1]
Sources: 6 · Level of evidence B1
Among patients with measurable disease at baseline, the objective radiological response rate was 17% in the gemcitabine group and 4% in the supportive-care group (P = .048).
The median OS was 16.4 months (95% CI, 11.6–20.2) in the gemcitabine group and 13.4 months (95% CI, 12.4–17.8) in the supportive care group (HR, 0.90; 95% CI, 0.60–1.34; P = .60).
Grade 3 or higher treatment-related adverse events occurred in 52% of patients in the gemcitabine group and 16% of patients in the supportive-care group. One patient in the gemcitabine group died of a treatment-related serious adverse event (grade 5 infection).
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Malignant peritoneal mesothelioma arises from the mesothelial cells of the peritoneum and spreads within the confines of the abdominal cavity. There have been few prospective clinical trials conducted in this patient population. Most clinical evidence arises from single-center retrospective studies. Male sex and sarcomatoid or biphasic subtype disease are correlated with poor prognosis.[19,20]
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are offered to patients with diffuse malignant peritoneal mesothelioma, no extraperitoneal disease spread, a good performance status, and an expectation to achieve complete surgical cytoreduction. Among centers with expertise in this form of therapy, reported median survival for appropriately selected patients approaches 3 to 4 years.[19,20]
A large multi-institutional registry study evaluated cytoreductive surgery combined with HIPEC in patients with diffuse, malignant, peritoneal mesothelioma.[19] Among 401 patients, 187 (46%) had complete or near-complete cytoreduction, and 372 (92%) received HIPEC. Of the patients who received HIPEC, 311 (83%) received cisplatin and doxorubicin. The median follow-up period was 33 months (range, 1–235 months).
Sources: 19
A large multi-institutional registry study evaluated cytoreductive surgery combined with HIPEC in patients with diffuse, malignant, peritoneal mesothelioma.[19] Among 401 patients, 187 (46%) had complete or near-complete cytoreduction, and 372 (92%) received HIPEC. Of the patients who received HIPEC, 311 (83%) received cisplatin and doxorubicin. The median follow-up period was 33 months (range, 1–235 months).
Grade 3 to 4 complications occurred in 127 of 401 patients (31%), and 9 patients (2%) died perioperatively.
The median actuarial OS was 53 months, with survival rates of 81% at 1 year, 60% at 3 years, and 47% at 5 years.
Prognostic factors associated with improved survival on multivariate analysis included epithelioid histological subtype, absence of lymph node metastases, complete or near complete resection, and the use of HIPEC.
A second multi-institutional report included 211 patients treated at three centers in the United States (who were not part of the previous study).[20] All patients underwent cytoreductive surgery and HIPEC using either cisplatin or mitomycin. In patients with malignant peritoneal mesothelioma, the efficacy of pemetrexed plus cisplatin appeared comparable with that seen in patients with pleural mesothelioma, and the regimen was well tolerated. Prospective phase II or III clinical trials of this regimen have not been conducted in patients with peritoneal mesothelioma.
Sources: 20
A second multi-institutional report included 211 patients treated at three centers in the United States (who were not part of the previous study).[20] All patients underwent cytoreductive surgery and HIPEC using either cisplatin or mitomycin. In patients with malignant peritoneal mesothelioma, the efficacy of pemetrexed plus cisplatin appeared comparable with that seen in patients with pleural mesothelioma, and the regimen was well tolerated. Prospective phase II or III clinical trials of this regimen have not been conducted in patients with peritoneal mesothelioma.
The actuarial OS was 38 months. The survival rates were 41% at 5 years and 26% at 10 years.
Prognostic factors associated with improved survival were age younger than 60 years, complete or near-complete gross resection, low versus high histological grade, and the use of cisplatin versus mitomycin.
In the U.S. Pemetrexed Expanded Access Program, 98 patients (9.3%) had peritoneal mesothelioma, 57 patients were previously treated, and 38 patients were chemotherapy-naive.[21] Of the 73 patients with malignant peritoneal mesothelioma and measurable disease, 28 patients were chemotherapy-naive and 43 patients were previously treated. Twenty-six patients received single-agent pemetrexed, and 47 patients received pemetrexed and cisplatin. Carboplatin may be substituted for cisplatin.
Sources: 21
In the U.S. Pemetrexed Expanded Access Program, 98 patients (9.3%) had peritoneal mesothelioma, 57 patients were previously treated, and 38 patients were chemotherapy-naive.[21] Of the 73 patients with malignant peritoneal mesothelioma and measurable disease, 28 patients were chemotherapy-naive and 43 patients were previously treated. Twenty-six patients received single-agent pemetrexed, and 47 patients received pemetrexed and cisplatin. Carboplatin may be substituted for cisplatin.
The overall response rate was 26%. Similar objective response rates were achieved in previously treated and chemotherapy-naive patients.
The median OS for previously treated patients was 13.1 months; it had not been reached at the time of the analysis for chemotherapy-naive patients.
As expected, both response rate (29% vs. 19%) and median survival (13.1 vs. 8.7 months) were higher for patients who received the pemetrexed doublet than for those who received pemetrexed alone in this nonrandomized study.
These results were comparable with those seen in pleural mesothelioma.
In the International Pemetrexed Expanded Access Program, 29 evaluable patients with peritoneal mesothelioma received pemetrexed 500 mg/m2 and carboplatin, dosed at an area under the curve of 5.[22]
Sources: 22
In the International Pemetrexed Expanded Access Program, 29 evaluable patients with peritoneal mesothelioma received pemetrexed 500 mg/m2 and carboplatin, dosed at an area under the curve of 5.[22]
Seven patients (24%) had objective responses (one complete), and 52% had stable disease.
These results were comparable with those achieved with pemetrexed and cisplatin.
The pemetrexed/cisplatin/bevacizumab and nivolumab/ipilimumab regimens that improved OS were conducted exclusively in patients with malignant pleural mesothelioma. Data to support the efficacy and safety of these regimens in patients with malignant peritoneal mesothelioma are required.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment of patients with recurrent malignant mesothelioma usually involves procedures and agents not previously used in the initial treatment attempt. No standard treatment approaches have improved survival or controlled symptoms for a prolonged period. Selected patients with localized disease recurrence may be candidates for additional chest wall resection.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Treatment options for recurrent malignant mesothelioma include:
Patients who have not received previous systemic therapy are candidates for first-line chemotherapy, chemoimmunotherapy, or dual immune checkpoint inhibition. For more information, see the Treatment of Advanced Malignant Mesothelioma (Stages II, III, and IV) section.
Sources: Treatment of Advanced Malignant Mesothelioma (Stages II, III, and IV)
Systemic therapy for recurrent malignant mesothelioma previously treated with first-line chemotherapy or immunotherapy.
Sources: Systemic therapy
Systemic therapy for recurrent malignant mesothelioma previously treated with first-line chemotherapy or immunotherapy.
Gemcitabine in combination with ramucirumab.
Pemetrexed.
Sources: Pemetrexed
Nivolumab.
Sources: Nivolumab
Vinorelbine.
Sources: Vinorelbine
Patients with disease recurrence are candidates for phase I and II clinical trials that evaluate new targeted therapies, biological therapies, chemotherapeutic agents, or physical approaches.[1-8]
Selected patients with localized disease recurrence may be candidates for additional chest-wall resection. One trial of 47 carefully selected patients at a single institution indicated that chest-wall resection could be safely performed. Time-to-recurrence from initial resection appeared to predict the expected survival benefit and was factored into decision making.[9][Level of evidence C1]
Sources: 9 · Level of evidence C1
Systemic therapy
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (gemcitabine in combination with ramucirumab):
A multicenter, randomized, double-blind, placebo-controlled, phase II trial (RAMES [NCT03560973]) included 161 patients with malignant pleural mesothelioma that progressed during or after first-line treatment with pemetrexed plus platinum. Patients were randomly assigned (1:1) to receive either gemcitabine plus ramucirumab, an anti-VEGFR-2 antibody (n = 80), or gemcitabine plus placebo (n = 81). The primary end point was overall survival (OS).[10] Of note, patients enrolled in the RAMES trial had no previous exposure to bevacizumab or immune checkpoint inhibitors.
A multicenter, randomized, double-blind, placebo-controlled, phase II trial (RAMES [NCT03560973]) included 161 patients with malignant pleural mesothelioma that progressed during or after first-line treatment with pemetrexed plus platinum. Patients were randomly assigned (1:1) to receive either gemcitabine plus ramucirumab, an anti-VEGFR-2 antibody (n = 80), or gemcitabine plus placebo (n = 81). The primary end point was overall survival (OS).[10] Of note, patients enrolled in the RAMES trial had no previous exposure to bevacizumab or immune checkpoint inhibitors.
The median OS was 13.8 months (70% confidence interval [CI], 12.7–14.4) in the gemcitabine-plus-ramucirumab group and 7.5 months (70% CI, 6.9–8.9) in the gemcitabine-plus-placebo group (hazard ratio [HR], 0.71; 70% CI, 0.59–0.85; P = .028).[10][Level of evidence A1]
Sources: 10 · Level of evidence A1
The median progression-free survival (PFS), although longer in the gemcitabine-plus-ramucirumab group, was not significantly different (HR, 0.79; 70% CI, 0.66–0.94; P = .082).
More patients who received gemcitabine plus ramucirumab had controlled disease than patients who received gemcitabine plus placebo (73% [70% CI, 66%–78%] vs. 52% [70% CI, 46%–58%]).
Grade 3 to 4 treatment-related adverse events were reported in 35 of 80 patients (44%) who received gemcitabine plus ramucirumab and 24 of 81 patients (30%) who received gemcitabine plus placebo.
There were no treatment-related deaths in either study group.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (pemetrexed):
A large randomized study compared pemetrexed with best supportive care in 243 patients who received one previous regimen of chemotherapy that did not include pemetrexed.[11][Level of evidence A1]
Sources: 11 · Level of evidence A1
A large randomized study compared pemetrexed with best supportive care in 243 patients who received one previous regimen of chemotherapy that did not include pemetrexed.[11][Level of evidence A1]
No survival benefit was shown in patients who received pemetrexed, although the PFS rate, time-to-progression, and the response rates favored the pemetrexed arm.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (nivolumab):
A multicenter, placebo-controlled, double-blind, randomized, phase III trial (CONFIRM [NCT03063450]) included 332 patients with malignant pleural or peritoneal mesothelioma and disease progression after previous first-line platinum-based chemotherapy. Patients were randomly assigned (2:1) to receive either nivolumab, an anti–programmed death 1 (PD-1) antibody, at a flat dose of 240 mg intravenously every 2 weeks (n = 221), or placebo (n = 111) until disease progression or a maximum of 12 months. Co-primary end points were investigator-assessed PFS and OS.[12]
A multicenter, placebo-controlled, double-blind, randomized, phase III trial (CONFIRM [NCT03063450]) included 332 patients with malignant pleural or peritoneal mesothelioma and disease progression after previous first-line platinum-based chemotherapy. Patients were randomly assigned (2:1) to receive either nivolumab, an anti–programmed death 1 (PD-1) antibody, at a flat dose of 240 mg intravenously every 2 weeks (n = 221), or placebo (n = 111) until disease progression or a maximum of 12 months. Co-primary end points were investigator-assessed PFS and OS.[12]
The median OS was 10.2 months (95% CI, 8.5–12.1) in the nivolumab group and 6.9 months (95% CI, 5.0–8.0) in the placebo group (HR, 0.69; 95% CI, 0.52–0.91; P = .0090). Programmed death-ligand 1 (PD-L1) expression was not predictive of response to treatment for either OS or PFS based on a positivity threshold of 1%.
At a median follow-up of 11.6 months, the median PFS was 3.0 months (95% CI, 2.8–4.1) in the nivolumab group and 1.8 months (95% CI, 1.4–2.6) in the placebo group (HR, 0.67; 95% CI, 0.55–0.85; P = .0012).[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
The overall response rate was 11% in the nivolumab group and 1% in the placebo group (odds ratio, 14.0; 95% CI, 2.4–not estimable; P = .00086).
Serious adverse events occurred in 41% of patients in the nivolumab group and 44% of patients in the placebo group. There were no treatment-related deaths in either group.
Source: Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 12, 2025. Captured 2026-09-09.
Evidence (vinorelbine):
A multicenter, open-label, randomized, phase II trial (VIM [NCT02139904]) included 154 patients with malignant pleural mesothelioma and disease progression after previous platinum-based chemotherapy. Patients were randomly assigned (2:1) to receive either active symptom control (ASC) with oral vinorelbine (n = 98) or ASC alone (n = 56) every 3 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary end point was PFS.[13] The clinical impact of vinorelbine monotherapy for treatment of relapsed malignant pleural mesothelioma is limited, with a modest improvement in PFS and no difference in OS. This clinical impact should be weighed against the potential impact on quality of life caused by treatment-related adverse events.
A multicenter, open-label, randomized, phase II trial (VIM [NCT02139904]) included 154 patients with malignant pleural mesothelioma and disease progression after previous platinum-based chemotherapy. Patients were randomly assigned (2:1) to receive either active symptom control (ASC) with oral vinorelbine (n = 98) or ASC alone (n = 56) every 3 weeks until disease progression, unacceptable toxicity, or withdrawal. The primary end point was PFS.[13] The clinical impact of vinorelbine monotherapy for treatment of relapsed malignant pleural mesothelioma is limited, with a modest improvement in PFS and no difference in OS. This clinical impact should be weighed against the potential impact on quality of life caused by treatment-related adverse events.
The median PFS was 4.2 months in the ASC-plus-vinorelbine group and 2.8 months in the ASC-alone group (adjusted HR, 0.60; 80% CI [upper limit, 0.70]; one-sided adjusted log-rank P < .001).[13][Level of evidence B1]
Sources: 13 · Level of evidence B1
The median OS did not differ significantly between the two groups (9.3 months in ASC-plus-vinorelbine group vs. 9.1 months in the ASC-alone group).
The objective response rate was 3% in the ASC-plus-vinorelbine group and 2% in the ASC-alone group.
Although BRCA1 expression is required for vinorelbine-induced apoptosis in preclinical models, and loss of expression may correlate with vinorelbine resistance, low BRCA1 expression did not correlate with clinical activity in this study.
Vinorelbine was generally well tolerated and most treatment-related adverse events in both groups were mild to moderate in severity. The most common serious adverse events in the ASC-plus-vinorelbine group versus the ASC-alone group were dyspnea (5% vs. 0%), lower respiratory tract infection (5% vs. 6%), unspecified infection (3% vs. 0%), and febrile neutropenia (3% vs. 0%). Treatment-related deaths were reported in two patients in the ASC-plus-vinorelbine group (caused by pneumonia and lower respiratory tract infection) and in one patient in the ASC-alone group (caused by lower respiratory tract infection).
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment options for mesothelioma
The following types of treatment are used:
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The following surgical treatments may be used for mesothelioma in the chest:
Wide local excision is surgery to remove the cancer and some of the healthy tissue around it. The amount of healthy tissue removed depends on how deep or how large the tumor being removed is.
Pleurectomy and decortication is surgery to remove part of the covering of the lungs and lining of the chest and part of the outside surface of the lungs.
Sources: lungs
Extrapleural pneumonectomy is surgery to remove one whole lung and part of the lining of the chest, the diaphragm, and the lining of the sac around the heart.
Sources: Extrapleural pneumonectomy · diaphragm
Pleurodesis is surgery that uses chemicals or drugs to make a scar in the space between the layers of the pleura. Fluid is first drained from the space using a catheter or chest tube and the chemical or drug is put into the space. The scarring stops the build-up of fluid in the pleural cavity.
Sources: Pleurodesis · pleura · pleural cavity
After the doctor removes all the cancer that can be seen at the time of the surgery, some people may receive chemotherapy or radiation therapy to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.
Sources: chemotherapy · radiation therapy · adjuvant therapy
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. It may also be used as palliative care to relieve symptoms and improve quality of life.
Sources: x-rays · External radiation therapy · palliative care · quality of life
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Combination chemotherapy is the use of more than one anticancer drug.
Systemic chemotherapy is when chemotherapy is taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body.
Sources: injected
Regional chemotherapy is when chemotherapy is placed directly into an organ or a body cavity, such as the chest or peritoneum. When given this way, the drugs mainly affect cancer cells in those areas. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a type of regional chemotherapy used to treat mesothelioma:
Sources: cavity · peritoneum · Hyperthermic intraperitoneal chemotherapy
HIPEC may be used to treat mesothelioma that has spread to the peritoneum (tissue that lines the abdomen and covers most of the organs in the abdomen). After the surgeon removes all the cancer that can be seen, a solution containing anticancer drugs is heated and pumped into and out of the abdomen to kill cancer cells that remain. Heating the anticancer drugs may kill more cancer cells.
Sources: abdomen
The way the chemotherapy is given depends on the type and stage of the cancer being treated.
Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.
Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer
Visit Drugs Approved for Malignant Mesothelioma for more information.
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Immunotherapy helps a person's immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.
Immunotherapy drugs used to treat advanced mesothelioma include:
ipilimumab
Sources: ipilimumab
nivolumab
Sources: nivolumab
Other immunotherapy drugs, such as durvalumab, are being studied in mesothelioma.
Sources: durvalumab
Learn more about Immunotherapy to Treat Cancer.
Sources: Immunotherapy to Treat Cancer
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Bevacizumab is a targeted therapy drug used to treat mesothelioma.
Sources: Bevacizumab
Other targeted therapies, such as ramucirumab, are being studied in mesothelioma.
Sources: ramucirumab
Learn more about Targeted Therapy to Treat Cancer.
Sources: Targeted Therapy to Treat Cancer
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of localized mesothelioma (stage I)
If stage I mesothelioma is in one part of the chest lining, treatment may include surgery to remove the cancer and the tissue around it.
Sources: stage I mesothelioma
Treatment of stage I intracavitary mesothelioma may include:
Sources: intracavitary
a surgery called extrapleural pneumonectomy
Sources: extrapleural pneumonectomy
palliative surgery with pleurectomy and decortication, which may be followed by radiation therapy, to relieve symptoms and improve quality of life
Sources: decortication
palliative radiation therapy to relieve symptoms and improve quality of life
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of advanced mesothelioma (stages II, III, and IV)
If stage II, stage III, or stage IV mesothelioma is found in the chest, treatment may include:
immunotherapy (nivolumab and ipilimumab)
Sources: nivolumab · ipilimumab
combination chemotherapy with or without targeted therapy (bevacizumab)
Sources: bevacizumab
combination chemotherapy and palliative care, which may be followed by maintenance chemotherapy
palliative care, which may include draining fluid from the chest, a procedure to prevent fluid from collecting in the chest (pleurodesis), surgery, or radiation therapy, to relieve symptoms and improve quality of life
Sources: palliative care · pleurodesis
chemotherapy placed directly into the chest or abdominal cavity to shrink the tumors and keep fluid from building up
Sources: cavity
If stage II, stage III, or stage IV mesothelioma is found in the peritoneum, treatment may include:
Sources: peritoneum
surgery to remove the tumor followed by hyperthermic intraperitoneal chemotherapy
chemotherapy
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment of recurrent mesothelioma
When mesothelioma recurs (comes back), the treatment strategy often involves options that weren’t used in the initial treatment. If you haven’t received systemic therapy before, treatment may include:
chemotherapy
Sources: chemotherapy
a combination of chemotherapy and immunotherapy (nivolumab)
Sources: immunotherapy · nivolumab
immunotherapy alone
If you have received systemic therapy, treatment might include the following, given alone or in combination:
chemotherapy
immunotherapy
For certain people with locally recurrent cancer, surgery to remove the affected part of the chest wall may be an option.
Sources: locally recurrent cancer
Source: Mesothelioma Treatment, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Side effects of treatment
Treatment for mesothelioma may cause side effects. For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Malignant Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma, Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Mesothelioma
ClinicalTrials.gov recordPleural Neoplasms
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordPleural Mesothelioma, Malignant Pleural Mesothelioma
ClinicalTrials.gov recordAdvanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordAdvanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
ClinicalTrials.gov recordAdvanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
ClinicalTrials.gov recordAdvanced Malignant Mesothelioma, Recurrent Malignant Mesothelioma
ClinicalTrials.gov recordAdvanced Malignant Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma
ClinicalTrials.gov recordMalignant Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordMalignant Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordPleural Mesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordEpithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
ClinicalTrials.gov recordMalignant Mesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordPleural Malignant Mesothelioma
ClinicalTrials.gov recordPleural Mesothelioma, Peritoneal Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma, Adenocarcinoma of Lung, Pancreatic Neoplasms
ClinicalTrials.gov recordMalignant Peritoneal Mesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordUnresectable Pleural or Peritoneal Malignant Mesothelioma
ClinicalTrials.gov recordEpithelioid Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma, Stage II Pleural Mesothelioma, Stage III Pleural Mesothelioma, Stage IV Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma, Peritoneal Carcinomatosis
ClinicalTrials.gov recordMesothelioma, Malignant
ClinicalTrials.gov recordBiphasic Mesothelioma, Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Malignant...
ClinicalTrials.gov recordAdvanced Malignant Solid Neoplasm, Advanced Peritoneal Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent...
ClinicalTrials.gov recordRecurrent Pleural Malignant Mesothelioma, Stage IV Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma, Mesothelioma
ClinicalTrials.gov recordPleural Epithelioid Mesothelioma, Pleural Malignant Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordEsophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal
ClinicalTrials.gov recordMesothelioma, BAP1 Loss of Function
ClinicalTrials.gov recordPleural Malignant Mesothelioma
ClinicalTrials.gov recordPleural Mesothelioma Malignant Advanced
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordPleural Malignant Mesothelioma
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordBiphasic Mesothelioma, Epithelioid Mesothelioma, Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7, Stage IB...
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMalignant Mesothelioma (MPM)
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma, Malignant
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma, Malignant
ClinicalTrials.gov recordMalignant Pleural Mesothelioma
ClinicalTrials.gov recordPleural Mesothelioma Malignant Advanced
ClinicalTrials.gov recordPleural Carcinomatosis
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordPleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB...
ClinicalTrials.gov recordAdvanced Malignant Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
ClinicalTrials.gov recordMesothelioma
ClinicalTrials.gov recordMesothelioma; Lung
ClinicalTrials.gov recordMesothelioma, Peritoneal Mesothelioma
ClinicalTrials.gov recordTreatment of Advanced Malignant Mesothelioma (Stages II, III, and IV)
Malignant Mesothelioma
Treatment of Recurrent Malignant Mesothelioma
Treatment of Localized Malignant Mesothelioma (Stage I)